JP6962915B2 - 改善されたｔｎｆ結合因子 - Google Patents

改善されたｔｎｆ結合因子 Download PDF

Info

Publication number
JP6962915B2
JP6962915B2 JP2018524836A JP2018524836A JP6962915B2 JP 6962915 B2 JP6962915 B2 JP 6962915B2 JP 2018524836 A JP2018524836 A JP 2018524836A JP 2018524836 A JP2018524836 A JP 2018524836A JP 6962915 B2 JP6962915 B2 JP 6962915B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
binding
tnf
isvd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018524836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506839A (ja
JP2019506839A5 (OSRAM
Inventor
バイセ，マリー−アンジュ
ブクノー，ヨアヒム
カステールス，ペーテル
ヘーク，ジーノ ヴァン
Original Assignee
アブリンクス エン．ヴェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブリンクス エン．ヴェー． filed Critical アブリンクス エン．ヴェー．
Publication of JP2019506839A publication Critical patent/JP2019506839A/ja
Publication of JP2019506839A5 publication Critical patent/JP2019506839A5/ja
Priority to JP2021168871A priority Critical patent/JP7357038B2/ja
Application granted granted Critical
Publication of JP6962915B2 publication Critical patent/JP6962915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Organic Insulating Materials (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
JP2018524836A 2015-11-12 2016-11-14 改善されたｔｎｆ結合因子 Active JP6962915B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021168871A JP7357038B2 (ja) 2015-11-12 2021-10-14 改善されたｔｎｆ結合因子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562254375P 2015-11-12 2015-11-12
US62/254,375 2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en) 2015-11-12 2016-11-14 Improved tnf binders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021168871A Division JP7357038B2 (ja) 2015-11-12 2021-10-14 改善されたｔｎｆ結合因子

Publications (3)

Publication Number Publication Date
JP2019506839A JP2019506839A (ja) 2019-03-14
JP2019506839A5 JP2019506839A5 (OSRAM) 2019-12-12
JP6962915B2 true JP6962915B2 (ja) 2021-11-10

Family

ID=57348648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018524836A Active JP6962915B2 (ja) 2015-11-12 2016-11-14 改善されたｔｎｆ結合因子
JP2021168871A Active JP7357038B2 (ja) 2015-11-12 2021-10-14 改善されたｔｎｆ結合因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021168871A Active JP7357038B2 (ja) 2015-11-12 2021-10-14 改善されたｔｎｆ結合因子

Country Status (37)

Country Link
US (2) US10544211B2 (OSRAM)
EP (2) EP3266798A3 (OSRAM)
JP (2) JP6962915B2 (OSRAM)
KR (2) KR20240029115A (OSRAM)
CN (1) CN108473563B (OSRAM)
AU (2) AU2016352943B2 (OSRAM)
BR (1) BR112018009714A8 (OSRAM)
CA (2) CA3005085C (OSRAM)
CL (1) CL2018001291A1 (OSRAM)
CO (1) CO2018005915A2 (OSRAM)
CR (1) CR20180311A (OSRAM)
CY (1) CY1120303T1 (OSRAM)
DK (1) DK3191511T3 (OSRAM)
DO (1) DOP2018000122A (OSRAM)
EC (1) ECSP18042569A (OSRAM)
ES (1) ES2662418T3 (OSRAM)
GT (1) GT201800095A (OSRAM)
HK (1) HK1248716A1 (OSRAM)
HR (1) HRP20171949T1 (OSRAM)
HU (1) HUE035805T2 (OSRAM)
IL (2) IL259269B2 (OSRAM)
LT (1) LT3191511T (OSRAM)
MA (1) MA41653A (OSRAM)
MD (1) MD3191511T2 (OSRAM)
ME (1) ME02954B (OSRAM)
MX (1) MX385207B (OSRAM)
NO (1) NO2768984T3 (OSRAM)
PE (1) PE20181317A1 (OSRAM)
PH (1) PH12018501025A1 (OSRAM)
PL (1) PL3191511T3 (OSRAM)
PT (1) PT3191511T (OSRAM)
RS (1) RS56676B1 (OSRAM)
SG (1) SG11201803975SA (OSRAM)
SI (1) SI3191511T1 (OSRAM)
SM (1) SMT201700590T1 (OSRAM)
TN (1) TN2018000159A1 (OSRAM)
WO (1) WO2017081320A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022020666A (ja) * 2015-11-12 2022-02-01 アブリンクス エン．ヴェー． 改善されたｔｎｆ結合因子

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
EP3693386A1 (en) 2014-05-16 2020-08-12 Ablynx NV Immunoglobulin variable domains
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CN114980923A (zh) * 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽
MX2022006880A (es) 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
JP2023553694A (ja) 2020-12-18 2023-12-25 アブリンクス エン．ヴェー． ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
EP4435002A4 (en) * 2021-11-29 2025-03-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. MODIFIED PROTEIN OR POLYPEPTIDE
JP2025540914A (ja) * 2022-11-04 2025-12-17 セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド Ｎｌｒｐ１２およびｎｌｒｃ５モジュレーター、ならびにそれらを使用して疾患を調節する方法
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
KR20250151445A (ko) 2023-02-17 2025-10-21 아블린쓰 엔.브이. 신생아 fc 수용체에 결합하는 폴리펩티드

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
HK1041210A1 (zh) 1998-02-19 2002-07-05 埃克斯西特治疗公司 用於调节淋巴细胞活化的组合物及方法
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
NZ563471A (en) 2002-11-08 2009-04-30 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
BRPI0406694B8 (pt) 2003-01-10 2021-05-25 Ablynx Nv polipeptídios terapêutico, seus homólogos, seus fragmentos, que são usados nas modulações da agregação plaquetária
PT1639011E (pt) 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
EP1863847A2 (en) 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
SI2444424T1 (sl) 2005-05-20 2018-10-30 Ablynx N.V. Izboljšana protitelesa (TM) za zdravljenje z agregacijo posredovanih motenj
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP5049973B2 (ja) 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ 慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌
JP2009517069A (ja) 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2012130874A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
RU2010151725A (ru) 2008-05-16 2012-06-27 Аблинкс Нв (Be) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
SG173173A1 (en) * 2009-02-19 2011-08-29 Glaxo Group Ltd Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2010115998A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
CN102574914A (zh) 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CA3141978A1 (en) * 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
WO2013024059A2 (en) * 2011-08-17 2013-02-21 Glaxo Group Limited Modified proteins and peptides
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP3693386A1 (en) * 2014-05-16 2020-08-12 Ablynx NV Immunoglobulin variable domains
NO2768984T3 (OSRAM) 2015-11-12 2018-06-09
WO2017137579A1 (en) * 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022020666A (ja) * 2015-11-12 2022-02-01 アブリンクス エン．ヴェー． 改善されたｔｎｆ結合因子
JP7357038B2 (ja) 2015-11-12 2023-10-05 アブリンクス エン．ヴェー． 改善されたｔｎｆ結合因子

Also Published As

Publication number Publication date
HUE035805T2 (en) 2018-05-28
MA41653A (fr) 2018-01-09
SG11201803975SA (en) 2018-06-28
PH12018501025A1 (en) 2019-01-28
RU2018120524A3 (OSRAM) 2020-09-24
CA3005085C (en) 2024-09-10
RS56676B1 (sr) 2018-03-30
US9745372B2 (en) 2017-08-29
IL310373A (en) 2024-03-01
JP2019506839A (ja) 2019-03-14
ES2662418T3 (es) 2018-04-06
NO2768984T3 (OSRAM) 2018-06-09
IL259269B2 (en) 2024-07-01
LT3191511T (lt) 2018-01-10
SMT201700590T1 (it) 2018-01-11
EP3191511A1 (en) 2017-07-19
BR112018009714A2 (en) 2018-11-21
KR20180083382A (ko) 2018-07-20
US20170267752A1 (en) 2017-09-21
HK1248716A1 (en) 2018-10-19
CR20180311A (es) 2018-10-18
DK3191511T3 (en) 2018-01-08
GT201800095A (es) 2019-08-15
CO2018005915A2 (es) 2018-06-20
PE20181317A1 (es) 2018-08-14
ECSP18042569A (es) 2018-07-31
CY1120303T1 (el) 2019-07-10
MX2018005992A (es) 2019-01-31
AU2016352943A1 (en) 2018-06-07
IL259269B1 (en) 2024-03-01
PL3191511T3 (pl) 2018-03-30
IL259269A (en) 2018-07-31
US10544211B2 (en) 2020-01-28
CN108473563A (zh) 2018-08-31
EP3266798A2 (en) 2018-01-10
TN2018000159A1 (en) 2019-10-04
AU2016352943B2 (en) 2022-10-20
KR20240029115A (ko) 2024-03-05
JP2022020666A (ja) 2022-02-01
HRP20171949T1 (hr) 2018-01-26
CL2018001291A1 (es) 2018-09-14
CA3005085A1 (en) 2017-05-18
PT3191511T (pt) 2017-11-30
US20170190769A1 (en) 2017-07-06
MX385207B (es) 2025-03-04
ME02954B (me) 2018-07-20
KR102641194B1 (ko) 2024-02-26
AU2023200113A1 (en) 2023-02-16
DOP2018000122A (es) 2018-09-30
CA3234178A1 (en) 2017-05-18
SI3191511T1 (en) 2018-01-31
MD3191511T2 (ro) 2018-03-31
EP3266798A3 (en) 2018-03-28
EP3191511B1 (en) 2017-09-20
BR112018009714A8 (pt) 2019-02-26
CN108473563B (zh) 2022-06-14
JP7357038B2 (ja) 2023-10-05
WO2017081320A1 (en) 2017-05-18
RU2018120524A (ru) 2019-12-13

Similar Documents

Publication Publication Date Title
JP7357038B2 (ja) 改善されたｔｎｆ結合因子
US10544216B2 (en) P2X7 receptor antagonists and agonists
US20230242677A1 (en) Multi-specific antibodies
RU2774823C2 (ru) Усовершенствованные агенты, связывающие tnf
HK1238660B (en) Improved tnf binders
HK1238660A1 (en) Improved tnf binders
WO2025223473A1 (zh) 抗gdf-15抗体及其应用
TW202547861A (zh) 抗gdf-15抗體及其應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211014

R150 Certificate of patent or registration of utility model

Ref document number: 6962915

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250